Intracavitary administration of biological agents Journal Article
| Author: | Markman, M. |
| Article Title: | Intracavitary administration of biological agents |
| Abstract: | The intracavitary delivery of biological agents is based on sound pharmacologic, immunologic, and physiologic rationales. Results of early-stage clinical trials have confirmed both an advantage for exposure of the body cavity to the biologicals as compared with that of the systemic circulation following intracavitary drug delivery, as well as the suggestion of definite clinical utility. Trials that are in progress and those planned for the future will hopefully define optimal drug combinations, concentrations, and treatment schedules. Ultimately, randomized controlled trials will be required to define a role for such therapy as compared with standard therapeutic approaches to diseases principally confined to body cavities. © 1987 Raven Press, Ltd., New York. |
| Keywords: | cancer chemotherapy; cancer combination chemotherapy; antineoplastic agents; alpha interferon; bcg vaccine; interleukin 2; ovary cancer; antibodies, monoclonal; gamma interferon; ovary carcinoma; short survey; ovarian carcinoma; adjuvants, immunologic; glycoproteins; therapy; interleukin-2; tumor necrosis factor; female genital system; peritoneum; biological response modifiers; intraperitoneal drug administration; injections, intraperitoneal; drug mixture; interferons; human; picibanil; intracavitary antineoplastic therapy |
| Journal Title: | Journal of Biological Response Modifiers |
| Volume: | 6 |
| Issue: | 4 |
| ISSN: | 0732-6580 |
| Publisher: | Lippincott-Raven |
| Date Published: | 1987-08-01 |
| Start Page: | 404 |
| End Page: | 411 |
| Language: | English |
| PUBMED: | 2442312 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 5 February 2021 -- Source: Scopus |
